Healthcare is an ever changing with new treatments, innovative molecules and new devices being developed at an ever-increasing pace.
Photo by D-Koi | Unsplashed
Healthcare is an ever changing with new treatments, innovative molecules and new devices being developed at an ever-increasing pace. In most instances, new treatments or devices are priced above formulary standards. This poses a challenge for most funders to justify funding new innovative molecules or treatments as there is no clinical basis or rationale upon which to base the decision. Hence, despite of the benefit which innovation brings, pharmaceutical companies and device manufacturers quite often find that there is an expectation to demonstrate the clinical and economic value of their new products.
We provide technical and consulting support to companies which are looking to launch new products, apply for routine funding or engage healthcare funders. We aim to facilitate patient access to new molecules that although priced above formulary standards, have compelling overall value. i.e. they are medicines that produce better outcomes and are safe®, potentially enabling lower total cost of care for targeted patient populations. We define success as getting new molecules into a reimbursed framework or being involved in the ongoing monitoring and enhancement of value performance. Where a “negative” response is received from funders, a response that is clear, definitive and reasoned is also valuable as it either stops further fruitless effort or provides specifics to work on to achieve success (i.e. entry and permanent position in the market).
We believe our work with both suppliers and funders puts us in a unique position to effectively bridge the gap between them. The insights we have gained through consulting on both sides, together with the analytical capability to handle complex healthcare data, facilitates productive engagement and problem solving. Our service offering to pharmaceutical companies include health technology assessments, localisation of global clinical dossiers, construction of patient journey based on local experience, cost benefit analysis, cost effectiveness analysis, funder engagement support and ongoing measurement.